OraSure Technologies Marketing Mix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
OraSure Technologies Bundle
Go Beyond the Snapshot—Get the Full Strategy
Discover how OraSure Technologies syncs product innovation, pricing, distribution, and promotion to capture market share—this preview only hints at the insight inside. Purchase the full 4Ps Marketing Mix Analysis for an editable, presentation-ready deep dive with real data and strategic recommendations. Save time and apply expert-ready frameworks to your projects instantly.
Product
Rapid infectious-disease tests
OraSure’s rapid infectious-disease tests target point-of-care and OTC use with oral-fluid HIV assays like the FDA-approved OraQuick in‑home HIV test and CLIA-waived workflows for professional settings, delivering results in minutes. The noninvasive oral-swab format and minimal equipment needs improve uptake and accuracy for clinics, pharmacies and home users. With ~38.4 million people living with HIV globally (UNAIDS 2022), these tests support public-health screening and linkage-to-care.
Substance abuse screening
OraSure offers oral-fluid drug tests and saliva alcohol screens for workplace, rehabilitation and law-enforcement use, supporting observed collection and tamper-resistant kits that deliver rapid on-site results (minutes) versus typical urine lab turnaround of 24–72 hours; the US conducts ≈10 million workplace drug screens annually. Panel flexibility and configurable cutoffs allow alignment with employer or DOT policies, and devices integrate with lab confirmation workflows (GC‑MS/LC‑MS/MS) for chain-of-custody compliance.
Molecular collection & stabilization
OraSure's molecular collection and stabilization kits provide saliva, microbiome and other specimen collection with DNA/RNA stabilization from collection to analysis, offering room-temperature stability and standardized yields compatible with PCR, NGS and common lab workflows. They serve research institutions, clinical laboratories and biobanks and enable scalable sampling for decentralized and at-home studies. The platform supports high-throughput processing and integration into longitudinal and population studies.
Integrated kits & accessories
- Bundle: buffers, controls, instructions
- Security: barcodes, tamper-evident, return-mail
- Training & QC: materials, tools
- Scale: multi-site support, study logistics
Regulatory-backed quality
OraSure leverages FDA clearances (eg, FDA-cleared OraQuick HIV test) and CE marking for select products, backed by ISO-aligned quality systems; clinical validation and performance claims are published transparently with IFUs and multilingual labeling, plus post-market support and updates aligned to evolving 2024–2025 regulatory guidance.
- Regulatory: FDA clearance, CE where applicable
- Transparency: published clinical data, clear performance claims
- Support: IFUs, multilingual labels, post-market feedback
- Compliance: product updates per 2024–2025 standards
Noninvasive oral tests enable rapid at-home HIV, drug screening and scalable remote studies
OraSure's product suite—OraQuick oral HIV, oral-fluid drug/alcohol screens, and molecular saliva collection kits—prioritizes noninvasive, rapid point-of-care and at‑home testing with CLIA‑waived workflows and room‑temp stabilization. OraQuick (FDA‑cleared) and integrated kits enable scalable remote return-mail programs and multi‑site studies; global HIV burden ~38.4M (UNAIDS 2022), US ≈10M workplace drug screens/year.
| Product | Use case | Time-to-result | Key stat |
|---|---|---|---|
| OraQuick | At‑home/POC HIV | Minutes | FDA‑cleared; 2004 first approval |
| Drug/Alcohol | Workplace/Forensic | Minutes | US ≈10M screens/yr |
| Collection Kits | Research/Clinical | Stabilized RT | Compatible PCR/NGS |
What is included in the product
Detailed Word Document
Delivers a company-specific deep dive into OraSure Technologies’ Product, Price, Place, and Promotion strategies—ideal for managers, consultants, and marketers needing a compact but data-grounded marketing positioning analysis; structured for easy repurposing in reports, presentations, or strategy work.
Customizable Excel Spreadsheet
Condenses OraSure Technologies’ 4P insights into an at-a-glance, leadership-ready summary that relieves briefings and decision bottlenecks; customizable fields let teams adapt messaging for decks, workshops, or cross-functional alignment, helping non-marketing stakeholders quickly grasp strategic direction.
Place
Direct sales to healthcare
In 2024 OraSure (NASDAQ: OSUR) deployed dedicated sales teams to serve clinics, hospitals, public health programs and reference labs, prioritizing high-need geographies and integrated delivery networks. Teams provide onboarding, training and account management to accelerate adoption and reduce client churn. Sales squads coordinate stocking and replenishment to ensure continuity of care and minimize stockouts.
Distributor and channel partners
OraSure Technologies (NASDAQ: OSUR), founded in 1988, leverages regional distributors for market access, tender participation and last-mile logistics to extend its oral-fluid and point-of-care diagnostics reach. Set SLAs for cold-chain (when applicable) and inventory turns to protect sample integrity and reduce stockouts. Enable co-marketing and localized technical support with partners to drive adoption and expand reach in international and hard-to-serve markets.
Retail and pharmacy OTC
Place OraSure OTC self-tests in national retailers and pharmacy chains (CVS, Walgreens, Walmart) to maximize consumer convenience and leverage over 21,000 US community pharmacy touchpoints. Optimize shelf placement and planograms to boost visibility and conversion near related categories. Support pharmacist education for product guidance and counseling; CDC estimates ~1.2 million people living with HIV in the US, underscoring local demand. Use retailer POS and data-sharing to align inventory with community prevalence.
E-commerce and DTC
OraSure (NASDAQ: OSUR) sells via its company site and major marketplaces to maximize accessibility, pairs DTC subscriptions and bulk packs for program/research buyers, provides clear instructions, FAQs and tele-support links, and uses tracked shipping with discreet packaging to protect user privacy.
- company: OSUR
- channels: site + marketplaces
- offerings: subscriptions + bulk packs
- support: FAQs + tele-support
- logistics: tracked, discreet
Programmatic and institutional
Programmatic and institutional sales supply government tenders, NGOs, employers and schools with volume-based fulfillment, integrating with lab networks for confirmatory testing and enabling centralized billing across drop-ship to multiple sites while aligning deliveries to screening campaign schedules.
- Volume tenders: government, NGOs, schools
- Lab integration: confirmatory testing
- Logistics: drop-ship + centralized billing
- Timing: sync with screening campaigns
Expanded sales teams reach 21,000+ US pharmacies and institutional channels
In 2024 OraSure (NASDAQ: OSUR) expanded dedicated sales teams for clinics, hospitals and public-health programs, coordinating stocking and replenishment. The company leverages regional distributors and pharmacy chains to reach over 21,000 US community pharmacy touchpoints and international hard-to-serve markets. OTC, DTC and institutional channels (tenders, schools, employers) enable programmatic volume fulfillment and lab integration for confirmatory testing.
| Metric | Value |
|---|---|
| Pharmacy touchpoints | 21,000+ (US) |
| CDC US HIV estimate | ~1.2M people (2023–24) |
| Channel mix | Retail / DTC / Institutional / Distributors |
What You See Is What You Get
OraSure Technologies 4P's Marketing Mix Analysis
The preview shown here is the actual OraSure Technologies 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises. It delivers a complete, editable review of Product, Price, Place and Promotion with concise, actionable insights for strategic decisions. You’ll download the identical, ready-to-use file immediately after checkout.
Promotion
Clinical evidence & KOLs
Publish peer-reviewed performance and real-world studies—leveraging OraSure’s FDA approval of the OraQuick HIV self-test (2012) and data from settings serving about 39 million people living with HIV globally to substantiate claims. Partner with KOLs and public health agencies for advocacy and present at major conferences and webinars to educate stakeholders. Translate evidence into simple benefit messaging focused on accuracy, access and rapid results.
Targeted professional outreach
Run targeted campaigns to clinicians, lab directors, and occupational health buyers using live demos, sample programs, and CE-accredited trainings to drive adoption of OraSure’s FDA-cleared OraQuick over-the-counter HIV test (cleared 2012). Provide side-by-side comparison charts versus legacy lab methods and nurture leads with clinical case studies and interactive ROI calculators to shorten procurement cycles and increase conversion.
Consumer education for OTC
Develop culturally sensitive instructions and how-to videos for OraSure's FDA-cleared OraQuick OTC HIV self-test, with multilingual subtitles and pictograms; use social, search, and pharmacy media to highlight screening benefits and drive uptake; emphasize privacy, 20-minute speed and high specificity/clinical reliability; include clear linkage-to-care resources and local referral directories for the 39+ million people living with HIV globally.
Partnerships & public health initiatives
Partner with NGOs and local health departments to run community testing events and grant-funded programs, aligning OraSure materials and co-branding with awareness months like World AIDS Day and National HIV Testing Day to boost uptake; CDC estimates 1.2 million people living with HIV in the US with ~13% undiagnosed, underscoring need. Report impact metrics (tests distributed, positivity rate, linkage-to-care) to demonstrate outcomes and attract funding.
- Co-branded kits for NGOs/local health departments
- Events tied to World AIDS Day, National HIV Testing Day
- Track tests distributed, positivity, linkage-to-care
- Use metrics to secure grant and government funding
Digital content & support
OraSure Technologies (Nasdaq: OSUR) maintains up-to-date product pages, IFUs, and troubleshooting guides, pairs 24/7 chat, email and phone support for users and professionals, and supplies onboarding toolkits for new accounts while using marketing automation to drive segmented follow-up and higher engagement.
- Nasdaq: OSUR
- Updated IFUs & troubleshooting
- Chat, email, phone support
- Onboarding toolkits
- Marketing automation for segmentation
Scale at-home HIV testing: boost distribution, positivity detection, and linkage-to-care
Promote OraQuick OTC through peer-reviewed evidence, KOL advocacy, targeted clinical campaigns, multilingual how-to assets and community partnerships tied to awareness days to drive testing, linkage-to-care and procurement. Use metrics (tests distributed, positivity, linkage) and marketing automation to convert buyers and secure grants.
| Metric | Value | Source |
|---|---|---|
| FDA clearance | OraQuick OTC (2012) | FDA |
| People living with HIV (global) | ~39 million | UNAIDS 2023 |
| US PLHIV / undiagnosed | 1.2M / ~13% undiagnosed | CDC |
Price
Value-based pricing
Value-based pricing sets OraSure test prices to reflect FDA clearance and CLIA-waived use, strong clinical performance (peer-reviewed specificity >99%) and reduced workflow burden; compared with lab-based NAAT costs of roughly $100–150 per test this highlights per-patient savings. Position a premium tied to validated accuracy and regulatory backing while publishing transparent per-test economics and typical reimbursement rates for providers.
Tiered and volume discounts
OraSure employs tiered and volume discounts to serve large institutions, public health programs, and employers, structuring contract tiers by volume and term length to incentivize scale while protecting margins through committed forecasts. Starter bundles support pilots with scale-up incentives for multi-year renewals and forecasted minimums to maintain gross margins. Pricing flexibility enables deployment across clinical and workplace settings.
Global and access-oriented tiers
Adjust pricing via access programs for LMICs, which represent roughly 84% of the global population per World Bank classifications, coordinating with NGOs and national tenders to expand reach into public procurement channels. Balance affordability with commercial sustainability through tiered discounts and cost-sharing; explore local manufacturing and logistics to cut distribution costs and improve margins.
Bundles and subscriptions
OraSure bundles collection kits, accessories, training and phone support into total-solution offers (OraQuick HIV over-the-counter approval in 2012 underpins consumer trust), while subscription replenishment addresses recurring research and screening needs and prepaid service packages plus extended warranties simplify budgeting and cashflow predictability.
- Bundles: kits+training+support
- Subscriptions: recurring replenishment
- Prepaid packages & warranties
- Predictable costs for budgeting
Reimbursement and payment options
OraSure provides coding guidance and documentation to support reimbursement submissions where applicable, facilitates payer claims, enables multiple payment methods for OTC and DTC purchases (card, ACH, invoicing) and offers institutional credit terms subject to approval; pricing updates are aligned with market conditions and input costs to protect margins and competitiveness.
- Reimbursement support: coding/documentation
- Payments: multiple methods for OTC/DTC
- Institutional credit: approval-based terms
- Pricing: market- and input-cost aligned updates
Value-based FDA/CLIA test: >99% specificity; saves $100–150 vs lab NAAT
Value-based, premium pricing reflects FDA/CLIA positioning and peer-reviewed specificity >99%, highlighting savings versus lab NAAT costs of roughly $100–150 per test. Tiered volume discounts, starter bundles and subscription replenishment support scale and predictable revenue. LMIC access uses tiered discounts and partnerships (LMICs ≈84% of global population) while OraQuick OTC approval in 2012 underpins consumer trust.
| Metric | Value |
|---|---|
| Clinical specificity | >99% |
| Lab NAAT cost | $100–150/test |
| LMIC population share | ≈84% |
| OraQuick OTC approval | 2012 |